Topigen Initiates Dosing in Phase II Asthma Trial
Posted on: Friday, 1 February 2008, 12:00 CST
Topigen Pharmaceuticals has initiated patient dosing in a Phase II safety and efficacy study in asthma with one of its lead product candidates, TPI ASM8.
This study builds on prior pharmacodynamic and safety data in a three-day study of TPI ASM8 in an allergen challenge model and will be conducted in collaboration with leading clinical research centers across Europe, including the UK, Netherlands, France and Italy. TPI ASM8 is a novel, inhaled anti-inflammatory, RNA-targeting drug intended for the management of moderate to severe asthma.
The double-blind, randomized, placebo controlled crossover study in subjects with asthma will evaluate TPI ASM8 given once daily by inhalation in a breath-actuated inhaler over a 14-day period. TPI ASM8 acts primarily through inhibition of CCR3 and IL-5 receptors.
Mark Parry-Billings, chief development officer at Topigen, said: "TPI ASM8 is a truly innovative approach to the management of asthma and it is the first multi-targeted RNA antagonist to enter the clinic for the management of respiratory diseases."
Source: Datamonitor
Related Articles
- Angeion Corporation Launches Physician Office Program for COPD and Asthma Management
- Study: Asthma Linked to PTSD
- New Survey Indicates Need to Re-Think Approaches to Asthma Management in the U.S.
- Innovative In-School Asthma Management Program Launches to Aid New York City Children
- Allergy & Asthma Network Mothers of Asthmatics Changes Asthma Management for Patients
- Starlight Starbright Children's Foundation and The California Endowment Team Up to Provide Asthma Management Skills to School Staff in California
- Asthma Management Plans
- A Possible Change in Asthma Management
- Steroids Critical to Asthma Management
- Effect of Education on School-Age Children's and Parents' Asthma Management
 |
 |
User Comments (0)
RSS Feeds